AZD3470 for Advanced Solid Cancers
(PRIMROSE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called AZD3470 for individuals with advanced solid tumors lacking a specific protein (MTAP deficiency). The main goal is to determine if AZD3470 is safe and effective, either alone or with other cancer treatments. This study may suit those who have tried other cancer treatments without success and have a tumor with the MTAP deficiency. Participants must be willing to provide a tumor sample for testing and have a measurable tumor. As a Phase 1, Phase 2 trial, this research aims to understand how AZD3470 works in people and measure its effectiveness in an initial group, offering participants a chance to contribute to groundbreaking cancer treatment development.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that AZD3470 is likely to be safe for humans?
Research has shown that AZD3470 is a new treatment undergoing its first human tests. As it is in the early testing stages, limited information exists about its safety. The primary aim of these initial studies is to determine the safety and tolerability of AZD3470 for individuals with advanced solid cancers.
Researchers will closely monitor side effects to assess how well participants tolerate the treatment. AZD3470 acts as a PRMT5 inhibitor, targeting specific cancer cells. While this approach shows promise, its safety remains under study due to the treatment's early stage. Researchers carefully monitor participants to ensure their well-being throughout the trial.12345Why do researchers think this study treatment might be promising?
Researchers are excited about AZD3470 for advanced solid cancers because it introduces a novel approach by targeting specific cellular pathways that current treatments may not address. Unlike standard treatments, which often include chemotherapy or targeted therapies that act broadly, AZD3470 focuses on unique molecular mechanisms within cancer cells, potentially offering a more precise method of attack. This targeted action may lead to fewer side effects and improved effectiveness, providing hope for better outcomes in patients with advanced stages of solid tumors.
What evidence suggests that AZD3470 might be an effective treatment for advanced solid cancers?
Research has shown that AZD3470 targets an enzyme called PRMT5, which aids cancer cell growth. This enzyme is particularly active in tumors lacking a substance called MTAP, a condition common in several advanced solid cancers. Early lab studies suggest that AZD3470 might slow or stop tumor growth by blocking PRMT5. Although limited data exist from human studies, the drug's mechanism suggests it could be effective for these cancers. This trial examines how well AZD3470 is absorbed, its effects on the body, and its initial effectiveness in participants receiving AZD3470 monotherapy.12367
Are You a Good Fit for This Trial?
This trial is for adults with advanced or metastatic solid tumors that lack MTAP, a specific gene. Participants must have tried standard treatments without success and should be in fairly good health (able to perform daily activities with ease or some limitation). They need at least one tumor that can be measured by medical scans and should expect to live at least 12 more weeks.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive varying doses of AZD3470 to determine the optimal dose
Dose Optimization and Expansion
Participants receive optimized doses of AZD3470 to evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Follow-up
Participants are monitored for overall survival and progression-free survival
What Are the Treatments Tested in This Trial?
Interventions
- AZD3470
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology